Glutadope

TECHNOLOGY

• Novel therapeutic approach targeting the interaction between dopamine (D1R) and glutamate (NMDAR) receptors, involved in the mechanisms underlying addiction and depression

• Development of inhibitory compounds designed to disrupt this interaction without directly blocking the individual functions of the receptors

• Innovative therapeutic strategy aiming to improve treatment selectivity and potentially reduce side effects associated with existing therapies

MARKET

• Pharmaceutical and biotechnology industries specializing in psychiatric and neurological disorders

• Therapeutic applications in addiction treatment, particularly cocaine dependence

• Potential applications in depression treatment, addressing unmet medical needs associated with existing therapies

DEVELOPMENT STATUS

• TRL 3 – Preclinical proof of concept demonstrated in cellular and animal models

• Identification of several compounds inhibiting D1R-NMDAR interactions and modulating associated neuronal signaling pathways

• Promising initial in vivo results: compound 36 reduces cocaine-induced conditioned place preference in mice in a dose-dependent manner

• Preclinical validation of the therapeutic target in depression models, with antidepressant-like effects observed following disruption of D1R-NMDAR interactions

• Encouraging preliminary selectivity and tolerability findings. Further compound optimization and pharmacological studies are planned

IP

• Patent application filed on March 11, 2026

VALORISATION STRATEGY

• Seeking pharmaceutical or biotechnology industry partners for technology co-development

• Opportunity for direct technology licensing to an industrial partner